Neogenomics (NEO) Other Operating Expenses (2010 - 2026)

Neogenomics has reported Other Operating Expenses for 17 years, with the latest figure at $23.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 5.06% year-over-year to $23.8 million; the trailing twelve-month figure through Mar 2026 stood at $120.9 million (up 32.32% YoY), and the FY2025 full-year result was $119.8 million, up 41.47% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $23.8 million, down from $24.1 million in the prior quarter.
• The five-year high for Other Operating Expenses was $44.1 million in Q2 2025, with the low at $16.3 million in Q1 2023.
• Historically, Other Operating Expenses has averaged $21.8 million across 5 years, with a median of $20.2 million in 2024.
• Annual changes were most pronounced in 2022 — Other Operating Expenses decreased 0.89% — and 2025, when it surged 89.98%.
• Neogenomics' Other Operating Expenses stood at $17.1 million in 2022, then rose by 5.43% to $18.1 million in 2023, then jumped by 33.06% to $24.0 million in 2024, then rose by 0.1% to $24.1 million in 2025, then fell by 0.99% to $23.8 million in 2026.
• The last three Other Operating Expenses figures came in at $23.8 million (Q1 2026), $24.1 million (Q4 2025), and $28.9 million (Q3 2025), per Business Quant data.